Bacterial Diseases
Bacterial Diseases(细菌性疾病)
Bacterial Diseases 相关产品(602)
- GC52119Lansoprazole sulfone N-oxideCAS: 953787-54-7纯度: >98.00%
A potential impurity found in commercial preparations of lansoprazole
- GC521293-Amino-5-hydroxybenzoic AcidCAS: 76045-71-1纯度: >98.00%
A biosynthetic precursor to ansamycin antibiotics
- GC52171Clindamycin-d3 (hydrochloride)CAS: 1356933-72-6纯度: >99.00%
An internal standard for the quantification of clindamycin
- GC522117-[1-(1H)-Tetrazolylacetamido]desacetoxycephalosporanic AcidCAS: 56842-77-4纯度: >95.00%
A potential impurity in commercial preparations of cefazolin
- GC52303Ethyl MycophenolateCAS: 32483-51-5纯度: >98.00%
A potential impurity found in commercial preparations of mycophenolate mofetil
- GC523243-(3-Hydroxyphenyl)propionic Acid sulfateCAS: 86321-32-6纯度: >95.00%
A metabolite of certain phenols and glycosides
- GC52326Biotin-PEG4-LL-37 (human) (trifluoroacetate salt)纯度: >90.00%
A biotinylated and pegylated form of LL-37
- GC52346IDR 1002 (trifluoroacetate salt)纯度: >95.00%
A synthetic cationic innate defense regulator peptide
- GC52434Marbofloxacin-d8 (hydrochloride)纯度: >99.00%
An internal standard for the quantification of marbofloxacin
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC52101 | Brazilein | 600-76-0 | >95.00% | |
A phytochemical with diverse biological activities | ||||
| GC52119 | Lansoprazole sulfone N-oxide | 953787-54-7 | >98.00% | |
A potential impurity found in commercial preparations of lansoprazole | ||||
| GC52120 | DMPE-MPEG(2000) | 1254157-61-3 | >90.00% | |
A PEGylated form of DMPE | ||||
| GC52127 | Pexiganan (acetate) | 172820-23-4 | >98.00% | |
An antimicrobial peptide | ||||
| GC52129 | 3-Amino-5-hydroxybenzoic Acid | 76045-71-1 | >98.00% | |
A biosynthetic precursor to ansamycin antibiotics | ||||
| GC52133 | 12-Tridecenoic Acid | 6006-06-0 | >95.00% | |
A monounsaturated fatty acid | ||||
| GC52165 | Minosaminomycin | 51746-09-9 | >90.00% | |
An antibiotic | ||||
| GC52171 | Clindamycin-d3 (hydrochloride) | 1356933-72-6 | >99.00% | |
An internal standard for the quantification of clindamycin | ||||
| GC52211 | 7-[1-(1H)-Tetrazolylacetamido]desacetoxycephalosporanic Acid | 56842-77-4 | >95.00% | |
A potential impurity in commercial preparations of cefazolin | ||||
| GC52240 | BPH-1358 | 5352-53-4 | >95.00% | |
An inhibitor of UPPS and FPPS | ||||
| GC52303 | Ethyl Mycophenolate | 32483-51-5 | >98.00% | |
A potential impurity found in commercial preparations of mycophenolate mofetil | ||||
| GC52324 | 3-(3-Hydroxyphenyl)propionic Acid sulfate | 86321-32-6 | >95.00% | |
A metabolite of certain phenols and glycosides | ||||
| GC52326 | Biotin-PEG4-LL-37 (human) (trifluoroacetate salt) | - | >90.00% | |
A biotinylated and pegylated form of LL-37 | ||||
| GC52346 | IDR 1002 (trifluoroacetate salt) | - | >95.00% | |
A synthetic cationic innate defense regulator peptide | ||||
| GC52369 | Cecropin B (trifluoroacetate salt) | - | >95.00% | |
An antimicrobial peptide | ||||
| GC52378 | Cecropin A (trifluoroacetate salt) | - | >95.00% | |
An antimicrobial peptide | ||||
| GC52395 | Indolicidin (trifluoroacetate salt) | - | >98.00% | |
An antimicrobial peptide | ||||
| GC52406 | AMPR-22 (trifluoroacetate salt) | - | >95.00% | |
An antimicrobial peptide | ||||
| GC52416 | Histatin 5 (trifluoroacetate salt) | - | >98.00% | |
An antimicrobial peptide | ||||
| GC52434 | Marbofloxacin-d8 (hydrochloride) | - | >99.00% | |
An internal standard for the quantification of marbofloxacin | ||||
| GC52471 | 7(S),10(S)-DiHOME | 252255-87-1 | >95.00% | |
An antibacterial hydroxy fatty acid | ||||
| GC52483 | Fucosylated Ganglioside GM1 (porcine) (ammonium salt) | - | >98.00% | |
A sphingolipid | ||||
| GC52487 | Ganglioside GM4 (chicken egg) (ammonium salt) | - | >98.00% | |
A sphingolipid | ||||
| GC65195 | 2-O-Acetyl-20-hydroxyecdysone | 19536-25-5 | >99.00% | |
An ecdysone steroid hormone | ||||